Insights

Gathering insights about Casi…

Similar companies to Casi

Casi Tech Stack

Casi uses 8 technology products and services including Facebook Pixel, MySQL, Font Awesome, and more. Explore Casi's tech stack below.

Facebook Pixel
Analytics
MySQL
Database
Font Awesome
Font Scripts
jQuery Migrate
Javascript Libraries
Tawk.to
Live Chat
Elementor
Page Builders
X-XSS-Protection
Security
Nginx
Web Servers

Media & News

CASI Pharmaceuticals Announces Changes in Board Governance
James Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 19, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that its Board of Directors unanimously voted to appoint James Huang, a current independent board member, as Non-Executive Chairman of the Board, effective November 17, 2025. As part of this transition, Dr. Wei-Wu He will step down from the role as Executive Chairman and will remain a member of the Board of Directors.
Nov 19, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended September 30, 2025 (the "third quarter"). "We are focused on capitalizing and advancing our CID-103 clinical program in renal allograft antibody mediated rejection (AMR), first in the U.S. under an already approved IND, followed by China where a regulatory package has been accepted and is under review," said David Cory, CEO of CASI.
Nov 14, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a letter dated November 5, 2025, with a delisting determination from Nasdaq Stock Market LLC (the "Determination"). As previously reported, on May 5, 2025, Nasdaq notified the Company that its market value of listed securities (MVLS) had fallen below the minimum requirement of $35 million for 30 consecutive trading days, and as a result, did not comply with Listing Rule 5550(b)(2).
Nov 10, 2025 | www.accessnewswire.com
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.
Nov 04, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potential best-in-class, clinical stage anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced that data will be presented from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP) at the 67th American Society of Hematology Annual Meeting and Exposition being held December 6-9, 2025, in Orlando, Florida. Poster Presentation Details Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia Authors: Chen Yunfei, ZePing Zhou, Hu Zhou, Ruibin Huang, Zhenyu Yan, Jun Peng, Ming Hou, James Bussel, Alexander Zukiwski, Junping Chen, Lei Zhang Session Name: 311.
Nov 03, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Appoints James Huang to Board of Directors
- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 26, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced the appointment of James Huang as an Independent Director to the CASI Board of Directors, effective as of October 1, 2025. Mr. Huang brings over 35 years of experience building and investing in biopharma companies globally.
Sep 26, 2025 | www.accessnewswire.com

Casi's Email Address Formats

Casi uses at least 1 format(s):

Casi Email Formats	Example	Percentage
FLast@getcasi.com	JDoe@getcasi.com	32%
First@getcasi.com	John@getcasi.com	18%
FLast@getcasi.com	JDoe@getcasi.com	32%
First@getcasi.com	John@getcasi.com	18%

Frequently Asked Questions

Where is Casi's headquarters located?

Casi's main headquarters is located at Atlanta, GA US. The company has employees across 2 continents, including North AmericaSouth America.

What is Casi's stock symbol?

Casi is a publicly traded company; the company's stock symbol is CASI.

What is Casi's official website and social media links?

Casi's official website is getcasi.com and has social profiles on LinkedIn Crunchbase.

What is Casi's NAICS code?

Casi's NAICS code is 48-49 - Transportation and Warehousing.

How many employees does Casi have currently?

As of October 2025, Casi has approximately 9 employees across 2 continents, including North AmericaSouth America. Key team members include Chief Executive Officer: T. K.Senior Solutions Architect, Cto: D. G.Director Of Finance: L. G.. Explore Casi's employee directory with LeadIQ.

What industry does Casi belong to?

Casi operates in the Transportation, Logistics, Supply Chain and Storage industry.

What technology does Casi use?

Casi's tech stack includes Facebook PixelMySQLFont AwesomejQuery MigrateTawk.toElementorX-XSS-ProtectionNginx.

What is Casi's email format?

Casi's email format typically follows the pattern of FLast@getcasi.com. Find more Casi email formats with LeadIQ.

When was Casi founded?

Casi was founded in 2018.

Casi

Q: What is Casi's official website and social media links?

Casi's official website is getcasi.com. Casi has social profiles on LinkedIn.

Q: How many employees does Casi have currently?

Casi has approximately 9 employees.

Q: What technology does Casi use?

Casi's tech stack includes Google Workspace, React, Webpack, Shopify, YouTube.

Transportation, Logistics, Supply Chain and StorageGeorgia, United States2-10 Employees

Casi is transforming the way employers and employees connect around workforce scheduling and communication—without apps or logins. Our SMS-first platform helps organizations relay shift changes, manage callouts, and send announcements instantly, all through the tools employees already use: text messaging, messaging apps, and email.

Trusted by companies in warehousing, healthcare, hospitality, and retail, Casi enables real-time communication between managers and frontline teams. With automated scheduling tools, multilingual support, and actionable insights, we streamline operations and reduce turnover.

Whether you're overseeing 50 team members or 5,000, Casi helps you stay agile, engaged, and ahead of demand.

💬 Workforce scheduling and communication made simple.
🌐 Learn more: www.getcasi.com
📲 Book a demo: info@getcasi.com